Literature DB >> 23604709

Mechanical and energetic properties of papillary muscle from ACTC E99K transgenic mouse models of hypertrophic cardiomyopathy.

Weihua Song1, Petr G Vikhorev, Mavin N Kashyap, Christina Rowlands, Michael A Ferenczi, Roger C Woledge, Kenneth MacLeod, Steven Marston, Nancy A Curtin.   

Abstract

We compared the contractile performance of papillary muscle from a mouse model of hypertrophic cardiomyopathy [α-cardiac actin (ACTC) E99K mutation] with nontransgenic (non-TG) littermates. In isometric twitches, ACTC E99K papillary muscle produced three to four times greater force than non-TG muscle under the same conditions independent of stimulation frequency and temperature, whereas maximum isometric force in myofibrils from these muscles was not significantly different. ACTC E99K muscle relaxed slower than non-TG muscle in both papillary muscle (1.4×) and myofibrils (1.7×), whereas the rate of force development after stimulation was the same as non-TG muscle for both electrical stimulation in intact muscle and after a Ca²⁺ jump in myofibrils. The EC₅₀ for Ca²⁺ activation of force in myofibrils was 0.39 ± 0.33 μmol/l in ACTC E99K myofibrils and 0.80 ± 0.11 μmol/l in non-TG myofibrils. There were no significant differences in the amplitude and time course of the Ca²⁺ transient in myocytes from ACTC E99K and non-TG mice. We conclude that hypercontractility is caused by higher myofibrillar Ca²⁺ sensitivity in ACTC E99K muscles. Measurement of the energy (work + heat) released in actively cycling heart muscle showed that for both genotypes, the amount of energy turnover increased with work done but with decreasing efficiency as energy turnover increased. Thus, ACTC E99K mouse heart muscle produced on average 3.3-fold more work than non-TG muscle, and the cost in terms of energy turnover was disproportionately higher than in non-TG muscles. Efficiency for ACTC E99K muscle was in the range of 11-16% and for non-TG muscle was 15-18%.

Entities:  

Keywords:  animal models of human disease; calcium cycling/excitation-contraction coupling; efficiency; energy metabolism; hypertrophic cardiomyopathy

Mesh:

Year:  2013        PMID: 23604709      PMCID: PMC3680724          DOI: 10.1152/ajpheart.00951.2012

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  49 in total

Review 1.  The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms.

Authors:  J G Seidman; C Seidman
Journal:  Cell       Date:  2001-02-23       Impact factor: 41.582

2.  The use of the Peltier effect for simple and accurate calibration of thermoelectric devices.

Authors:  K M Kretzschmar; D R Wilkie
Journal:  Proc R Soc Lond B Biol Sci       Date:  1975-08-19

3.  Functional consequences of the mutations in human cardiac troponin I gene found in familial hypertrophic cardiomyopathy.

Authors:  F Takahashi-Yanaga; S Morimoto; K Harada; R Minakami; F Shiraishi; M Ohta; Q W Lu; T Sasaguri; I Ohtsuki
Journal:  J Mol Cell Cardiol       Date:  2001-12       Impact factor: 5.000

4.  The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model.

Authors:  Christopher Semsarian; Imran Ahmad; Michael Giewat; Dimitrios Georgakopoulos; Joachim P Schmitt; Bradley K McConnell; Steven Reiken; Ulrike Mende; Andrew R Marks; David A Kass; Christine E Seidman; J G Seidman
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

5.  Overexpression of the Na(+)/Ca(2+) exchanger and inhibition of the sarcoplasmic reticulum Ca(2+)-ATPase in ventricular myocytes from transgenic mice.

Authors:  C M Terracciano; K D Philipson; K T MacLeod
Journal:  Cardiovasc Res       Date:  2001-01       Impact factor: 10.787

6.  Cardiac performance as a function of intracellular oxygen tension in buffer-perfused hearts.

Authors:  K A Schenkman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-12       Impact factor: 4.733

7.  Cardiac troponin T mutations: correlation between the type of mutation and the nature of myofilament dysfunction in transgenic mice.

Authors:  D E Montgomery; J C Tardiff; M Chandra
Journal:  J Physiol       Date:  2001-10-15       Impact factor: 5.182

8.  Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy.

Authors:  Sara L Van Driest; Michele A Jaeger; Steve R Ommen; Melissa L Will; Bernard J Gersh; A Jamil Tajik; Michael J Ackerman
Journal:  J Am Coll Cardiol       Date:  2004-08-04       Impact factor: 24.094

Review 9.  Hypertrophic cardiomyopathy.

Authors:  Perry Elliott; William J McKenna
Journal:  Lancet       Date:  2004-06-05       Impact factor: 79.321

10.  Decreased energetics in murine hearts bearing the R92Q mutation in cardiac troponin T.

Authors:  Maryam M Javadpour; Jil C Tardiff; Ilka Pinz; Joanne S Ingwall
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

View more
  18 in total

Review 1.  Phenotyping cardiomyopathy in adult zebrafish.

Authors:  Alexey V Dvornikov; Pieter P de Tombe; Xiaolei Xu
Journal:  Prog Biophys Mol Biol       Date:  2018-05-30       Impact factor: 3.667

2.  Using baculovirus/insect cell expressed recombinant actin to study the molecular pathogenesis of HCM caused by actin mutation A331P.

Authors:  Fan Bai; Hannah M Caster; Peter A Rubenstein; John F Dawson; Masataka Kawai
Journal:  J Mol Cell Cardiol       Date:  2014-04-30       Impact factor: 5.000

3.  A dilated cardiomyopathy mutation blunts adrenergic response and induces contractile dysfunction under chronic angiotensin II stress.

Authors:  Ross Wilkinson; Weihua Song; Natalia Smoktunowicz; Steven Marston
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-10-02       Impact factor: 4.733

4.  Development of apical hypertrophic cardiomyopathy with age in a transgenic mouse model carrying the cardiac actin E99K mutation.

Authors:  Li Wang; Fan Bai; Qing Zhang; Weihua Song; Andrew Messer; Masataka Kawai
Journal:  J Muscle Res Cell Motil       Date:  2018-03-26       Impact factor: 2.698

5.  New insights provided by myofibril mechanics in inherited cardiomyopathies.

Authors:  Ying-Hsi Lin; Jonathan Yap; Chrishan J A Ramachandra; Derek J Hausenloy
Journal:  Cond Med       Date:  2019-10

6.  The dilated cardiomyopathy-causing mutation ACTC E361G in cardiac muscle myofibrils specifically abolishes modulation of Ca(2+) regulation by phosphorylation of troponin I.

Authors:  Petr G Vikhorev; Weihua Song; Ross Wilkinson; O'Neal Copeland; Andrew E Messer; Michael A Ferenczi; Steven B Marston
Journal:  Biophys J       Date:  2014-11-18       Impact factor: 4.033

Review 7.  Why Is there a Limit to the Changes in Myofilament Ca2+-Sensitivity Associated with Myopathy Causing Mutations?

Authors:  Steven B Marston
Journal:  Front Physiol       Date:  2016-09-26       Impact factor: 4.566

Review 8.  Phosphorylation of the regulatory light chain of myosin in striated muscle: methodological perspectives.

Authors:  Haiyang Yu; Samya Chakravorty; Weihua Song; Michael A Ferenczi
Journal:  Eur Biophys J       Date:  2016-04-15       Impact factor: 1.733

9.  Age- and strain-related aberrant Ca2+ release is associated with sudden cardiac death in the ACTC E99K mouse model of hypertrophic cardiomyopathy.

Authors:  Christina T Rowlands; Thomas Owen; Saheed Lawal; Shuangyi Cao; Samata S Pandey; Hsiang-Yu Yang; Weihua Song; Ross Wilkinson; Anita Alvarez-Laviada; Katja Gehmlich; Steven B Marston; Kenneth T MacLeod
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-09-08       Impact factor: 4.733

10.  Molecular Defects in Cardiac Myofilament Ca2+-Regulation Due to Cardiomyopathy-Linked Mutations Can Be Reversed by Small Molecules Binding to Troponin.

Authors:  Alice Sheehan; Andrew E Messer; Maria Papadaki; Afnan Choudhry; Vladimír Kren; David Biedermann; Brian Blagg; Anuj Khandelwal; Steven B Marston
Journal:  Front Physiol       Date:  2018-03-27       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.